



A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Register]

All Databases PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for Go Clear

Limits Preview/Index History Clipboard Details

- About Entrez
- Text Version
- Entrez PubMed
 - Overview
 - Help | FAQ
 - Tutorials
 - New/Noteworthy
 - E-Utilities
- PubMed Services
 - Journals Database
 - MeSH Database
 - Single Citation Matcher
 - Batch Citation Matcher
 - Clinical Queries
 - Special Queries
 - LinkOut
 - My NCBI
- Related Resources
 - Order Documents
 - NLM Mobile
 - NLM Catalog
 - NLM Gateway
 - TOXNET
 - Consumer Health
 - Clinical Alerts
 - ClinicalTrials.gov
 - PubMed Central

History has expired.

Display Abstract Show 20 Sort by Send to

All: 1 Review: 0

1: [Biochem Biophys Res Commun.](#) 1995 Jul 6;212(1):172-7. [Related Articles, Links](#)



Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.

[Lockwood K](#), [Moesgaard S](#), [Yamamoto T](#), [Folkers K](#).

Pharma Nord, Vejle, Denmark.

Over 35 years, data and knowledge have internationally evolved from biochemical, biomedical and clinical research on vitamin Q10 (coenzyme Q10; CoQ10) and cancer, which led in 1993 to overt complete regression of the tumors in two cases of breast cancer. Continuing this research, three additional breast cancer patients also underwent a conventional protocol of therapy which included a daily oral dosage of 390 mg of vitamin Q10 (Bio-Quinone of Pharma Nord) during the complete trials over 3-5 years. The numerous metastases in the liver of a 44-year-old patient "disappeared," and no signs of metastases were found elsewhere. A 49-year-old patient, on a dosage of 390 mg of vitamin Q10, revealed no signs of tumor in the pleural cavity after six months, and her condition was excellent. A 75-year-old patient with carcinoma in one breast, after lumpectomy and 390 mg of CoQ10, showed no cancer in the tumor bed or metastases. Control blood levels of CoQ10 of 0.83-0.97 and of 0.62 micrograms/ml increased to 3.34-3.64 and to 3.77 micrograms/ml, respectively, on therapy with CoQ10 for patients A-MRH and EEL.

- Publication Types:
- [Case Reports](#)

PMID: 7612003 [PubMed - indexed for MEDLINE]

Display Abstract Show 20 Sort by Send to

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
 Department of Health & Human Services
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)